Menu

Wellcome Sanger Institute Leaders Accused of Bullying

Several members of senior management at the prestigious UK research center face claims of sexism and mistreatment of staff.

Sep 4, 2018
Jef Akst

Update (October 30): An investigation by an independent lawyer “failings found in the way in which people have been managed,” but cleared Wellcome Sanger Institute Director Mike Stratton of discrimination, harassment, and misuse of funds, Nature reports.

ABOVE: WIKIMEDIA, MAGNUS MANSKE

The Wellcome Trust will be looking into several members of upper-level management at its Sanger Institute in Cambridge, UK, including director Sir Michael Stratton, regarding a suite of allegations from 10 former and current staff members. Claims include bullying and mistreatment, pressuring employees to quit, and not investigating grievances—problems, the complainants say, that female staff face more commonly than male staff do. 

Many of the complaints concern the turnover of staff at Sanger. The Guardian reports that the institution stands to lose some 25 percent of its faculty, including high-level positions such as the chief of scientific operations, within a year of receiving a regular five-year grant of more than £400 million (nearly $515 million). Staff have spoken out about the quick departure of many employees, who are sometimes asked to sign confidentiality agreements. “Many successful and high-profile scientists are reported to be in the category of leaving or have left the institute,” one former staff member told The Guardian anonymously.

See “Wellcome Trust Makes Reporting Harassment Mandatory

Earlier this year, the Wellcome Trust announced a new anti-bullying policy that would penalize institutions that didn’t report misconduct and defund researchers who have been found to have mistreated coworkers. Last month, geneticist Nazneen Rahman resigned from the Institute of Cancer Research (ICR) after being sanctioned by this new rule for harassment of her colleagues. 

See “Cancer Geneticist Quits After Harassment Allegations

Correction (September 4): The original version of this story stated that the Sanger Institute could lose 25 percent of its staff. Rather, the research center could lose 25 percent of its faculty. The Scientist regrets the error.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.